Myxedema Coma Market Outlook:
Myxedema Coma Market size was valued at USD 2.35 billion in 2025 and is set to exceed USD 3.68 billion by 2035, expanding at over 4.6% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of myxedema coma is estimated at USD 2.45 billion.
The reason behind the growth is impelled by a higher prevalence of diabetes 1. Type 1 diabetes could be linked to other diseases including Hashimoto’s thyroiditis, which is considered a major cause of hypothyroidism. Moreover, it causes damage to the thyroid gland and may reduce the level of thyroid hormones in the body. Globally, there were approximately 7 million people with type 1 diabetes in 2021.
The growing geriatric population is believed to fuel the myxedema coma market growth. The elderly population is more prone to thyroid dysfunction and other age-related diseases such as diabetes which may increase the risk of myxedema coma. Lately, over 8% of the world's population, is over the age of 65, and by 2050, this ratio is anticipated to rise to around 15%.
